Enhua preempted the first review! 2 billion

On December 11, NMPA's official website released the latest approved product information, Enhua Pharmaceuticals' 3 types of imitation market application for sci-fi injections was approved and evaluated, earlier only IDT approved imports and Yichang People's Fu Pharmaceuticals obtained domestic approval, the product for the annual sales of more than 2 billion pounds of heavy anaesthetic injections.
Figure 1: Enhua Pharmaceuticals' approval of the scissinesaffentini injection Source: NMPA Official Website Figure 2: Current approval of the scissine saffenitinib injection Source: Miennet one-click retrieval of saffentinib as a synthetic opioid, analgesic effect is about 5 to 10 times the effect of fentanine, the duration of the effect is twice that of fentanine.
earlier, the domestic IDT imported products as well as Yichang People's Fu Pharmaceuticals' domestic products, this Enhua Pharmaceuticals according to the new classification approved for listing as the same review, became the first enterprise to evaluate the product.
figure 3 The competition situation of acid shufentanil injection enterprises (units:%) Source: Minet China's public medical institutions terminal competition pattern Minet data show that sour Shufentany injection in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 2 billion yuan, Yichang people's pharmaceutical industry accounted for more than 90% of the share of the original research.
Table 1:2020 to date Enhua Pharmaceutical approved product situation source: MED2.0 China Drug Review Database 2020 to date, Enhua Pharmaceuticals in the field of neurological drugs in addition to obtaining the production approval of theacid saffentani injection, the company's other fist product Gaba spray capsule also passed the consistent evaluation.
This year according to the new classification of the declaration of the listing of the relying on Mimi ester emulsion, hydrochloric acid midazolam syrup, hydrochloric acid Lositin intestinal capsules are currently in the review and approval, if the follow-up can be successfully approved will further strengthen enhua pharmaceutical industry in the field of neurological drugs market position.
source: company announcement, Mienet database